NCT07174713View on ClinicalTrials.gov

REverse LuNg Airway and Vascular RemOdeling in Asthma ReMission (ReNORM)

NANot yet recruitingINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

October 31, 2025

Primary Completion Date

October 31, 2030

Study Completion Date

October 31, 2030

Conditions
Asthma; Eosinophilic
Interventions
BIOLOGICAL

Biologic Therapy

Participants with severe asthma (GINA 5) who are eligible to begin biologic therapy. Participants will undergo serial assessment with pulmonary imaging (CT, MRI), lung function testing, sputum collection, and symptom questionnaires. A subset of participants (\~15%) will be randomized to undergo MRI-guided bronchoscopy with airway sampling at baseline and 2 years.

Trial Locations (1)

N6A 5B7

Robarts Research Institute; The University of Western Ontario, London

All Listed Sponsors
collaborator

Canadian Institutes of Health Research (CIHR)

OTHER_GOV

lead

Western University, Canada

OTHER

NCT07174713 - REverse LuNg Airway and Vascular RemOdeling in Asthma ReMission (ReNORM) | Biotech Hunter | Biotech Hunter